SEC.06 // [Q&A REGISTER]
Tesamorelin: Frequently Asked Questions
Direct, cited answers to the questions people actually ask about tesamorelin — mechanism, IGF-1, half-life, safety, and regulatory scope.
How does tesamorelin work?
It binds the growth hormone-releasing hormone receptor on pituitary somatotrophs, raises cAMP, and stimulates pulsatile release of the body's own growth hormone, which in turn drives hepatic IGF-1 and visceral-fat lipolysis [4][7]. It acts upstream on the gland that makes growth hormone rather than supplying the hormone directly.
Is tesamorelin a growth hormone?
No. It is a synthetic GHRH analogue that prompts the pituitary to secrete endogenous growth hormone; it does not supply growth hormone directly, unlike recombinant GH [4]. The body's own pulsatile rhythm is amplified, not replaced [7].
Does tesamorelin raise IGF-1 levels?
Yes. In 13 healthy men, tesamorelin 2 mg/day for two weeks raised IGF-1 by 181 ug/L (P<0.0001) [4], and the pivotal HIV trial reported an 81.0% IGF-1 increase [1]. The IGF-1 rise persists across the once-daily interval even as the peptide clears quickly [7].
How does tesamorelin stimulate growth hormone release?
Through the Gs-coupled GHRH-receptor cascade — adenylyl cyclase, cAMP, PKA, then CREB phosphorylation — that drives GH gene transcription and granule exocytosis in an episodic, pulsatile pattern, as confirmed by PK-PD modeling [7][4]. The secretion comes in bursts rather than a flat continuous rise.
Does tesamorelin increase testosterone?
Tesamorelin acts on the growth hormone / IGF-1 axis, not the androgen axis; the research literature characterizes GH and IGF-1 effects, not a testosterone increase [4]. No tesamorelin trial reports testosterone as an outcome of its mechanism.
What is tesamorelin?
A stabilized synthetic 44-amino-acid analogue of human GHRH(1-44) bearing an N-terminal trans-3-hexenoic acid group [8]. It is the only FDA-approved agent of its class, indicated to reduce excess visceral abdominal fat in HIV-associated lipodystrophy [5].
What does tesamorelin do?
It amplifies the body's own pulsatile growth-hormone secretion and raises IGF-1, which together promote lipolysis preferentially in visceral adipose tissue [4][1]. In trials it selectively reduced visceral fat while leaving subcutaneous fat and BMI largely unchanged [1].
Will tesamorelin help me lose belly fat?
In HIV-associated lipodystrophy, tesamorelin 2 mg/day reduced visceral abdominal fat by 15.2% at 26 weeks versus a 5.0% increase on placebo [1]. Efficacy outside that studied population is not established by large randomized trials and would be off-label.
How long does it take to see fat loss from tesamorelin?
The pivotal trials measured significant visceral-fat reduction at 26 weeks, with further reduction sustained through 52 weeks of continued dosing [1][2]. A pooled analysis found no predictors of response identifiable at the 3-month mark [13].
Does tesamorelin burn belly fat?
It selectively reduced visceral (intra-abdominal) fat in HIV trials by stimulating GH/IGF-1-mediated lipolysis [1]. Subcutaneous fat and BMI generally changed little, so the effect is targeted to deep abdominal fat rather than overall weight [1].
Does tesamorelin increase the risk of diabetes or affect blood sugar?
In 13 healthy men neither fasting glucose (P=0.93) nor insulin-stimulated glucose uptake (P=0.61) changed significantly [4]. GH-axis stimulation can perturb glucose modestly, so monitoring is described for individuals with dysglycemia, though a dedicated type-2-diabetes trial found no significant HbA1c change.
Does tesamorelin work for fat loss in non-HIV users?
Non-HIV human data are limited to a mechanistic study in healthy men, in which it raised pulsatile GH and IGF-1 over two weeks [4][10]. No large general-population fat-loss randomized trial has been completed, so non-HIV efficacy is mechanistically plausible but unestablished and off-label.
Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?
In a 6-month JAMA RCT in HIV adults, tesamorelin reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) [3]. NAFLD/MASLD use remains investigational and off-label; the evidence was generated in HIV-associated fatty liver, not the general population.
How does tesamorelin affect the liver in NAFLD?
It lowered measured hepatic fat in HIV trials, and a liver-tissue transcriptomic analysis found upregulated oxidative-phosphorylation genes with downregulated inflammatory pathways [3][6]. The pattern is consistent with GH/IGF-1-driven visceral-fat lipolysis rather than a direct hepatic drug action.
Can tesamorelin reduce liver fat?
In the JAMA HIV trial it produced a net -2.9% reduction in hepatic fat fraction (P=0.003) [3], and a 2026 meta-analysis reported a pooled hepatic-fat reduction of -4.28% [15]. Those reductions were studied in HIV-associated fatty liver, not the general population.
What is the half-life of tesamorelin?
Plasma exposure is short — a non-clinical study reported a ~21 to 45 minute elimination half-life in dogs, and secondary human sources describe roughly 26 to 38 minutes — with apparent clearance near 1,060 L/h [8][7]. Downstream IGF-1 elevation nonetheless persists across the dosing interval, supporting once-daily use [4].
How long does tesamorelin stay in your system?
The parent peptide clears rapidly from plasma, but its biological effect — raised IGF-1 — lasts through the once-daily interval [7][4]. Population pharmacokinetics found no clinically relevant demographic covariates and a ~13% higher absorbed fraction by day 14 than day 1 [7].
What are the side effects of tesamorelin?
Trials report injection-site reactions and growth-hormone-class effects; the NIH LiverTox monograph rates it unlikely to cause clinically apparent liver injury (likelihood E), with no de novo serum-enzyme elevations reported in trials [5]. Long-term oncologic-safety data remain limited [2].
Does tesamorelin cause water retention?
Fluid-related effects are a recognized growth-hormone-class consideration; such GH-mediated reactions are among those monitored in the tesamorelin trials [2]. They reflect the growth-hormone axis the compound stimulates rather than a unique property of tesamorelin.
Who should not take tesamorelin / who should avoid it?
The research literature flags active malignancy as a labeled contraindication and notes growth-factor (IGF-1) concerns [5]. It is a prescription drug studied only for a specific HIV indication, not a general-use product, and it is prohibited in sport under WADA category S2.
Is tesamorelin FDA approved?
Yes, but only for one indication: NDA 022505 (November 2010) to reduce excess abdominal fat in HIV-infected adults with lipodystrophy [5]. Every other use — including general or cosmetic fat loss and anti-aging — is off-label and not FDA-approved.
What happens when you stop taking tesamorelin? Does the fat come back?
In the 52-week program, visceral fat reaccumulated upon discontinuation; the measured benefits were contingent on continued dosing [2]. The reduction was a maintained state rather than a permanent change, reversing within weeks of stopping.